Establishment Labs Holdings Inc
ESTA
Positions held
Your positionsESTA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Establishment Labs is positioned in a growing healthcare sector, focusing on innovative medical devices that cater to increasing demand for aesthetic procedures.
- Revenue increased by 13% compared to the prior quarter, reaching $68 million.
- Gross margin remained strong at 70.6%, indicating effective cost management despite operating challenges.
- The company faces significant financial challenges, with a high debt-to-equity ratio of 1220.32, raising concerns about financial stability.
- Net income for 2026-Q2 was -11.748 million, reflecting ongoing losses.
- Operating margin remains negative at -6.4%, highlighting persistent operational inefficiencies.
Fundamentals
| Market cap | $1.81B | Enterprise value | $2.00B | Trailing P/E | — | Forward P/E | 1,010.17 |
| PEG | — | Price / book | 83.60 | Beta | 1.06 | Dividend yield | 0.00% |
| Revenue growth | 31.7% | Earnings growth | — | Gross margin | 70.5% | Operating margin | -6.4% |
| Profit margin | -15.8% | ROE | -1.8% | ROA | -3.4% | Debt / equity | 12.20 |
| Current ratio | 3.84 | Free cash flow | -$19.29M | Analyst recommendation | strong_buy | Mean target | $102.44 |
| 52w high | $97.59 | 52w low | $38.38 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $67.5M | $59.9M | $64.6M | $53.8M | $51.3M |
| Op margin | -6.4% | -10.9% | -6.1% | -7.5% | -27.5% |
| Net income | -$11.7M | -$13.4M | -$2.6M | -$11.1M | -$16.6M |
| Gross margin | 70.6% | 70.7% | 70.5% | 70.1% | 68.8% |
| Gross profit | $47.7M | $42.3M | $45.5M | $37.7M | $35.3M |
| Operating income | -$4.3M | -$6.5M | -$3.9M | -$4.0M | -$14.1M |
- Revenue +13% vs prior quarter ($68M vs $60M).
- Gross margin 70.6% (was 70.7% prior quarter).
- Operating margin expanded to -6.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $211M | $166M | $165M | $162M | — |
| Op margin | -18.5% | -30.1% | -39.4% | -24.5% | — |
| Net income | -$51.1M | -$84.6M | -$78.5M | -$75.2M | — |
| Gross margin | 69.3% | 66.0% | 64.8% | 65.9% | — |
| Gross profit | $146M | $110M | $107M | $107M | — |
| Operating income | -$39.0M | -$50.0M | -$65.0M | -$39.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Establishment Labs Holdings (ESTA) Wins Expanded FDA Clearance, Is The Stock Still A Bargain?
2026-10-05 · Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®
2026-09-23 · Is Establishment Labs’ (ESTA) Profitability Inflection the Ultimate Buying Opportunity?
2026-09-08 · Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze.
2026-08-13 · Citigroup Upgrades Establishment Labs to Buy From Neutral, Price Target is $92
2026-08-12 · Baron Discovery Fund’s Strategic Trim of Establishment Labs Holdings Inc (ESTA) Locks Gains
2026-08-09 · Establishment Labs (ESTA) Stock Looks Fair On Cash Flow Yet Trades At A Premium On Sales
2026-08-06 · Establishment Labs Holdings Inc (ESTA) (Q2 2026) Earnings Call Highlights: U.S. Sales Surge 140. ...
2026-08-06 · Establishment Labs Q2 Earnings Call Highlights
2026-08-06 · Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates
Price (daily)
Full chart · RSI · MACD · patterns